Company / Return on Equity (ROE)
SAB Biotherapeutics, Inc. Return on Equity (ROE) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-131.3%
FY2025
5-year range
-131.3% / 261.5%
FY2021-FY2025
Trend
-78.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SAB Biotherapeutics, Inc. reports negative total equity of -131.3% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-131.3% in FY2025 with a 3-year CAGR of -87.4%.
Declined from -60.3% to -131.3% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -87.4pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- SAB Biotherapeutics, Inc.'s return on equity (roe) has declined for 4 consecutive years.
- In FY2025, return on equity (roe) decreased 78.3% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -131.3% | -78.3% |
| FY2024 | -73.6% | -22.0% |
| FY2023 | -60.3% | -37.3% |
| FY2022 | -44.0% | -116.8% |
| FY2021 | 261.5% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026